Revvity (RVTY)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$112.08-0.77%
Close 2026-07-07 · 1-day change
Reading RVTY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RVTY free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading RVTY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RVTY free→QuarterlyIQ Insights · RVTY
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $112.08. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $112 RVTY trades at 22× p/e, below its 37× p/e peer median, but our blended $105 fair value sits below the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $95–$125. Not investment advice.
$95.00 – $125.00 (median $116.00) · 6 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 15% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $5.71/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $116.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $85.82 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $79.08 | — | — | Hist. CAGR | high |
| graham number | 12M | $86.00 | — | — | TTM | high |
| Mgmt guidance | 12M | $197.21 | 36.5 | 5.40 | Mgmt | high |
| Peer EV/EBITDA | 12M | $19.17 | 6.2 | 6.51 | TTM | high |
| Peer P/FCF | 12M | $105.81 | 24.0 | 4.42 | TTM | high |
| Peer P/E | 12M | $186.98 | 36.5 | 5.12 | TTM | high |
| Peer P/S | 12M | $72.06 | 2.8 | 25.94 | TTM | high |
| PEG | 12M | $106.56 | 20.8 | 5.12 | TTM | high |
| residual income | 12M | $60.61 | — | — | TTM | high |
| Own P/E history | 12M | $113.75 | 22.2 | 5.12 | TTM | high |
| triangulated | 12M | $189.99 | 36.5 | 5.20 | Triangulated | high |
| Mgmt guidance | 3Y | $256.36 | 36.5 | 7.02 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $137.41 | 24.0 | 5.74 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $221.35 | 36.5 | 6.06 | Analyst | medium |
| Peer P/S | 3Y | $76.93 | 2.8 | 27.70 | guidance | medium |
| PEG | 3Y | $126.14 | 20.8 | 6.06 | Analyst | medium |
| Own P/E history | 3Y | $134.66 | 22.2 | 6.06 | Analyst | medium |
| Mgmt guidance | 5Y | $305.35 | 36.5 | 8.36 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $163.57 | 24.0 | 6.83 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $232.56 | 36.5 | 6.37 | Analyst | high |
| Peer P/S | 5Y | $80.83 | 2.8 | 29.10 | guidance | high |
| PEG | 5Y | $132.53 | 20.8 | 6.37 | Analyst | high |
| Own P/E history | 5Y | $141.48 | 22.2 | 6.37 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.